Frank R. Ruderman
Frank Ruderman is the Chief Executive Officer,
Chairman of the Board, and a Managing Partner of Tenex Greenhouse Ventures.
Additionally, Mr. Ruderman is the Chairman and CEO of Berkeley HeartLab.
He is also a founder of Tenex Medical Investors, an organization of
angel investors with an exclusive focus in the life sciences. He serves
on the Board of Directors of Watergate Software, and is also a member
of the Global Advisory Board of the Asian Business Association.
Mr. Ruderman had been a consultant and a director of Genomyx from its
founding at Genentech with Human Genome Project funding, later acting
as President/CEO and CFO. Genomyx was sold to Beckman Instruments. He
founded and acted President, COO and a Director of Physiometrix, which
went public at a $60 million valuation. Mr. Ruderman also helped to
found two additional medical device companies, Intella Interventional
(private) and Cardiac Pathways (public at a $200 million valuation)
as spin-outs of Physiometrix. Mr. Ruderman served as a Board member,
President, COO and CFO of American Bionetics, which saw revenue growth of
5x and its stock price increased to a high of 8x, the IPO price. The
Company was sold to BioGenex after finalizing two acquisitions and completing
joint ventures with Millipore and Dupont. He served as a member of the
Board and the first President/CEO of Mast Immunosystems, which was sold
to Hitachi. Before that, Mr. Ruderman served in various domestic and
international corporate executive positions with Pfizer Pharmaceuticals,
Pfizer Diagnostics and Millipore.
Mr. Ruderman has an M.B.A. from the Amos Tuck School of Business at
Dartmouth College, an M.A. in vascular physiology from Boston University,
and a B.S. in biology from Tufts University.
Robert E. Leach
Robert Leach is the President, Chief Operating
Officer, and a Managing Partner of Tenex Greenhouse Ventures. He is
responsible for smooth running the Greenhouse fund, ensuring that deals
are well represented and that there is sufficient deal flow.
Mr. Leach served as Chairman and CEO of EPIcyte Pharmaceutical. He completed
an angel financing followed by the Company's first venture capital round.
He also completed a strategic alliance with Dow Chemical providing some
$50 Million of value to the Company. Mr. Leach founded CEO Consulting
to assist biotechnology companies through transition, and typically would
serve as an interim CEO. He initiated and completed the merger of two
client companies. Mr. Leach was appointed Chief Operating Officer of
CONNECT, the University of California San Diego's innovative program
in Technology and Entrepreneurship. In this capacity he and the CONNECT
staff worked with over 300 early stage high technology companies. Mr.
Leach was formerly the President and Chief Executive Officer of Genencor
International. Genencor is now number 2 in its industry with revenues
of over $300 million and 1300 employees, and has been sold to Eastman
Kodak and Cultor Limited of Europe. Prior to Genecor, he worked at Corning
Inc.
Mr. Leach has an M.B.A. from the Smeal College of Business at Pennsylvania
State University and a B.S. from Pennsylvania State University.
Dr. Timothy Mills
Dr. Timothy Mills is a Managing Partner
of Tenex Greenhouse Ventures. His focus is on selecting portfolio companies
for which Sanderling might be interested in providing follow-on funding.
With over fifteen years of experience in biomedical research and corporate
management, Dr. Timothy Mills joined Sanderling as an Operating Partner
and was subsequently promoted to General Partner. At Sanderling, Dr.
Mills has focused on early stage investments in medical devices, biotherapeutics,
and i-Health. He serves Sanderling portfolio companies as Director, Chief
Executive Officer or management team member.
Prior to joining Sanderling, Dr. Mills served as the Corporate Vice
President of New Business Development and Chief Scientific Officer of
Target Therapeutics, a medical device company that was acquired by Boston
Scientific for $1.2 billion. He also served as the Director for Prograft
Medical, a Target affiliate. Prior to joining Target, Dr. Mills served
as Director of Business Development and Advanced Research & Development
in the Interventional Cardiology Division of Baxter Healthcare. Dr.
Mills' academic appointments include service as the Director of the
Artificial Heart Program at the University of California, Irvine Medical
Center and membership in the University of California, San Francisco
Radiology Department.
Dr. Mills received his Ph.D. in Bioengineering from the University of
California, Berkeley & San Francisco School of Medicine, his M.S.
in Electrical Engineering & Computer Science from the University
of California, Berkeley, and his B.S. in Electrical Engineering from
the University of Colorado, Boulder.
Paul D. Quadros
Paul D. Quadros is a Managing Partner of
Tenex Greenhouse Ventures. He is involved in the screening and selection
process of portfolio companies for the greenhouse.
Additionally, Mr. Quadros is currently Chairman of the Board of GenStar
Therapeutics Corp., a developer of gene therapies to treat Hemophilia
A and prostate cancer. Mr. Quadros is a founder of Tenex Medical Investors,
an organization of angel investors with an exclusive focus in the life
sciences. He served as Chairman of the Investment Screening Committee.
Mr. Quadros is a founder and Chairman of Cardiac Science, a developer
of automatic external defibrillator devices and software and TheraCyte,
Inc., a manufacturer and distributor of devices that allow human cell
transplants without immunosuppression. He is also a founder and serves
on the Board of Directors of cancerfacts.com, an Internet enabled disease
management tools company, and AuthCath Vascular Access, a developer
of proprietary venous access systems. Mr. Quadros is also an advisor
to ENDOcare, Inc., a developer and manufacturer of surgical systems and
devices and Spectrascan Health Services, the largest provider of mammography
services in the United States. Mr. Quadros also served as a consultant
and as a member of the Board of Directors of NeoVision Corporation,
a developer of diagnostic and image guided therapy equipment. NeoVision
was sold to U.S. Surgical Corporation.
Mr. Quadros founded GenStar and served as its President and CEO when
a strategic partnership alliance with Baxter Healthcare Corporation
was completed. He was a General Partner of Technology Funding, a venture
capital management organization. He joined Technology Funding as a Senior
Vice President and was elected a General Partner. Mr. Quadros was a
member of Technology Funding's Commitments Committee, also serving as
its Chairman. During his affiliation with Technology Funding, he also
served as Director of Investment Research and Director of Equity Investments.
Mr. Quadros served as Chairman of Technology Funding's Medical Investment
Committee and was actively involved in managing Technology Funding's
healthcare portfolio.
Mr. Quadros holds a B.A. in Finance from California State University
at Fullerton and an MBA from the UCLA Graduate School of Management.
Alfred J. Mandel
Mr. Mandel then founded a business development
firm: Big Idea Group (BIG). Mr. Mandel's current ventures also include
Tenex Medical, which is an angel investor network. Both Tenex and BIG
focus on helping emerging high technology companies grow and become
successful. Mr. Mandel sits on the board of several young high technology
companies, and is an industry advisor to life science and Internet related
firms.
In 1986 he left Apple to co-found Redgate Communications Corp. Redgate
grew to become a 120 employee marketing communications firm and an industry
leader in new media. Redgate was acquired by American Online in 1994.
In 1982 Apple Computer hired him as their printer product manager. After
introducing Apple's printers, Mr. Mandel helped roll out both the Apple
Lisa and Macintosh computers as marcom manager in Apple's Macintosh
Group. John Sculley then appointed him Apple's first "event marketing"
manager. Always an entrepreneur, at age 26 Mr. Mandel started his second
company: Photon Electronic Sales. Photon sold computer products in seven
European countries.
Mr. Mandel has studied electronics and environmental sciences and holds
an MA in Environmental Design from the University of Oregon's School
of Architecture.
Paul Goddard
This information is currently being updated.
David B. Swedlow, M.D.
Dr. Swedlow has spent the last 20 years
dedicated to the advancement of medical technology and patient safety.
He is currently a principal in 3xNell, LLC, a consulting and seed investing
firm concentrating in emerging medical technologies.
Serving as Senior Vice President of Medical Affairs and Technology Development
for Nellcor Puritan Bennett from 1987 through 1998, he established and
directed an advanced technology research team at Nellcor that developed
several innovative technologies for patient monitoring, including advances
in pulse oximetry. Prior to coming to Nellcor, Dr. Swedlow was an associate
professor of Anesthesiology at the University of Pennsylvania and Senior
Staff Physician at the Children's Hospital of Philadelphia in the Department
of Anesthesia and Critical Care Medicine. There, he established and directed
the department's clinical research program and achieved national and
international prominence in the fields of neurointensive care and respiratory
safety monitoring.
Brian D. Frenzel
Mr. Frenzel is an active angel investor
and founder and advisor to biomedical and high technology companies.
He serves on the boards of directors and the management advisory boards
of several private companies and non-profit organizations.
His management experience includes co-founding and serving as a senior
executive of Centaur Pharmaceuticals, a neurodegenerative disease pharmaceutical
discovery and development company, Vesta Medical, a medical device company,
and Genelabs Technologies, a biotechnology company. Prior to entering
the startup company arena, Mr. Frenzel was the Director of Corporate
Planning at Syntex Corporation, a Principal at Booz, Allen & Hamilton
and a Lieutenant in the United State Navy.
Mr. Frenzel holds a BS in physics and an MBA from Stanford University.
Allan W. May
Allan May has an extensive background in
negotiating strategic transactions and alliances, having completed the
acquisition, merger or sale of over 100 companies. In addition, he has
over 15 years of experience in the management and operation of life
science and high technology businesses.
Mr. May has been a Founder, board member or Chairman and CEO of a number
of early stage companies in the life sciences, eHealth and Internet
arenas including Intella Interventional Systems, MAST Immunosystems,
ImmuneTech, Quanam Medical, Z-Kat, BeHere, and NuGEN. Mr. May is currently
Chairman of the Investment Screening Committee of Tenex Medical Investors.
Tenex, a private angel investor organization of over 160 members located
in California, is the largest angel investor organization in the United
States devoted to life sciences investments. During 2000, Tenex members
invested over $15M in early and later stage life science companies.
Prior to 1996, Mr. May was Senior Vice President, Business Development
for Diasonics, Inc., a NYSE-listed medical imaging company manufacturing
and distributing MRI, ultrasound, fluoroscopic and therapeutic devices
worldwide. Prior to Diasonics, Mr. May was President and Chief Operating
Officer of Fortune Systems Corporation, a NASDAQ-traded developer of
microprocessor based file servers utilizing the Unix operating system.
Patrick G. Enright
Patrick Enright, is a partner at Diaz &
Altschul Group, LLC, a privately held merchant bank, and has been a
director of the Company since March 1998. From March 1995 to February
1998, Mr. Enright served in various executive positions at the Company,
including Senior Vice President, Corporate Development and Chief Financial
Officer.
From September 1993 to June 1994, Mr. Enright was Senior Vice President
of Finance and Business Development for Boehringer Mannheim Therapeutics,
a pharmaceutical company and a subsidiary of Corange Ltd. From September
1989 to September 1993, Mr. Enright was employed at Paine Webber Incorporated,
an investment banking firm, where he became a Vice President in January
1992.
Mr. Enright
received his M.B.A. from the Wharton School of Business at the University
of Pennsylvania and his B.S. in biological sciences from Stanford University.